Home / Health / New Drug Fights Superbugs by Stopping Biofilms
New Drug Fights Superbugs by Stopping Biofilms
19 Nov
Summary
- New treatment aims to prevent bacteria from forming protective biofilms.
- This approach complements antibiotics, reducing infection recurrence.
- Antimicrobial resistance is a growing global health challenge.

A groundbreaking strategy is emerging to tackle persistent bacterial infections, particularly those involving urinary tract infections (UTIs). This innovative approach focuses on preventing bacteria from forming protective layers known as biofilms, which are often resistant to antibiotic treatment.
These bacterial communities, adhering to surfaces like the urinary bladder lining, shield bacteria from antibiotics and the body's immune system. While conventional antibiotics may clear free-floating bacteria, surviving biofilm bacteria can lead to recurrent infections.
Dr. Jehangir Cama, co-founder of BioTryp Therapeutics, is developing a treatment that prevents bacteria from aggregating. This method is not a new antibiotic but a drug designed to keep bacteria separated, thus improving infection clearance when used with antibiotics and potentially preventing recurrence when used alone.
This development comes at a critical time, with antimicrobial resistance (AMR) identified as a major global health concern. The World Health Organization reported that approximately one in six bacterial infections in 2023 showed resistance to antibiotics.
BioTryp's research originated from Dr. Cama's doctoral work at the University of Cambridge. The venture, now led by CEO Dr. Ashraf Zarkan, recently received the 2026 ELRIG Drug Discovery Innovation Award.
Dr. Cama highlights that AMR is not solely a scientific issue but also economic and social. The difficulty in developing new antibiotics, due to limited sales and investment recovery challenges, contributes to a decline in research despite its importance.
The immediate goal is to identify and optimize a lead drug candidate for animal studies, followed by clinical trials. Funding is currently being sought for this lead optimization phase. Success in this venture could provide a crucial complementary tool against hard-to-treat bacterial infections.